Hui Wei
Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College · Blood diseases hospital · Blood Diseases Hospital, Chinese Academy of medical Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hui Wei as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:33 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07132684 · Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia PatientsInstitute of Hematology & Blood Diseases Hospital, China · recruiting · AML, Adult · principal investigator
- N/ANCT06991920 · Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous LineageInstitute of Hematology & Blood Diseases Hospital, China · not yet recruiting · Adult ALL, MPAL · principal investigator
- Ph2NCT06635681 · Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AMLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · AML (Acute Myelogenous Leukemia) · principal investigator
- Ph1/Ph2NCT06611839 · Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AMLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · AML, IDH1 Mutation, Treatment · principal investigator
- Ph2NCT06570915 · Daratumumab for T Cell ALL With MRD-positive After Standard ChemotherapyInstitute of Hematology & Blood Diseases Hospital, China · withdrawn · ALL, Adult · principal investigator
- Ph1/Ph2NCT06561880 · The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 MutationInstitute of Hematology & Blood Diseases Hospital, China · recruiting · FLT3 Gene Mutation, AML · principal investigator
- N/ANCT06529250 · Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · AML · principal investigator
- Ph1NCT06387082 · A Clinical Study of HMPL-506 in Patients With Hematological MalignanciesHutchmed · recruiting · Hematological Malignancies · principal investigator
- N/ANCT06066242 · Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense ChemotherapyInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · Acute Myeloid Leukemia · principal investigator
- N/ANCT03475095 · Motor Control Mechanisms by CNS of Tuina in Patients With Lumbar Disk HerniationThe First Affiliated Hospital of Zhejiang Chinese Medical University · unknown · Low Back Pain, Disc, Herniated · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 09:33 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- [A single-center, randomized controlled trial of PEG-rhG-CSF and common rhG-CSF to promote neutrophil recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia].Zhonghua Xue Ye Xue Za Zhi · 20193 citationsRCR 0.1
- [Homoharringtonine in newly diagnosed acute promyelocytic leukemia treatment: a prospective, randomized controlled trial].Zhonghua Xue Ye Xue Za Zhi · 20161 citationsRCR 0.0
- [Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study].Zhonghua Xue Ye Xue Za Zhi · 20220 citationsRCR 0.0